Synthesis, DNA binding, topoisomerase inhibition and cytotoxic properties of 2-chloroethylnitrosourea derivatives of Hoechst 33258

Biological and Pharmaceutical Bulletin

Volumn 28, Issue 6, 2005, Pages 1004-1009

  Bielawski, Krzysztof ^a   Bielawska, Anna ^a   Anchim, Tomasz ^a   Wołczyński, Sławomir ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Chloroethylnitrosourea; Cytotoxicity; DNA topoisomerase; DNA binding; Hoechst 33258; Ultrafiltration assay

Indexed keywords

2 CHLOROETHYLNITROSOUREA DERIVATIVE; 4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; 4 [6 [5 (4 METHYLPIPERAZIN 1 YL)BENZIMIDAZOL 2 YL]BENZIMIDAZOL 2 YL]PHENYL 2 [2 [3 (2 CHLOROETHYL) 3 NITROSOUREIDO] 3 METHYLBUTANAMIDO]ETHYL CARBAMATE; 4 [6 [5 (4 METHYLPIPERAZIN 1 YL)BENZIMIDAZOL 2 YL]BENZIMIDAZOL 2 YL]PHENYL 2 [2 [3 (2 CHLOROETHYL) 3 NITROSOUREIDO]ACETAMIDO]ETHYL CARBAMATE; 4 [6 [5 (4 METHYLPIPERAZIN 1 YL)BENZIMIDAZOL 2 YL]BENZIMIDAZOL 2 YL]PHENYL 2 [2 [3 (2 CHLOROETHYL) 3 NITROSOUREIDO]PROPANAMIDO]ETHYL CARBAMATE; DEOXYRIBONUCLEOTIDE; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; DOUBLE STRANDED DNA; NITROSOUREA DERIVATIVE; POLY(DEOXYADENYLATE DEOXYTHYMIDYLATE); UNCLASSIFIED DRUG;

ARTICLE; BASE PAIRING; BINDING AFFINITY; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CARBON NUCLEAR MAGNETIC RESONANCE; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL STRAIN MDA MB 231; CELL VIABILITY; CONTROLLED STUDY; DNA SYNTHESIS; DRUG CYTOTOXICITY; DRUG DNA BINDING; DRUG MECHANISM; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; MELTING POINT; PROTON NUCLEAR MAGNETIC RESONANCE; ULTRAFILTRATION;

ANIMALS; BISBENZIMIDE; CATTLE; CELL LINE, TUMOR; DNA; DNA TOPOISOMERASES; ENZYME INHIBITORS; HUMANS; NITROSOUREA COMPOUNDS; PROTEIN BINDING;

EID: 21144439018     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.28.1004     Document Type: Article

References (25)

1. Schabel F. M., Jr., Cancer Res., 23, 725-731 (1963).
2. Tong W. P., Kirk M. C., Ludlum D. B., Cancer Res., 42, 3102-3105 (1982).
3. Hartley J. A., Gibson N. W., Kohn K. W., Mattes W. B., Cancer Res., 46, 1943-1947 (1986).
4. Reddy B. S. P., Sharma S. K., Lown J. W., Curr. Med. Chem., 8, 475-508 (2001).
5. Neidle S., Nat. Prod. Rep., 18, 291-309 (2001).
6. Denny W. A., Curr. Med. Chem., 8, 533-544 (2001).
7. Bartulewicz D., Bielawski K., Bielawska A., Różański A., Eur. J. Med. Chem., 36, 461-467 (2001).
8. Cozzi P., Farmaco, 58, 213-220 (2003).
9. Spink N., Brown D. G., Skelly J. V., Neidle S., Nucleic Acids Res., 22, 1607-1612 (1994).
10. Neidle S., Biopolymers, 44, 105-121 (1997).
11. Mann J., Baron A., Opoku-Boahen Y., Johansson E., Parkinson G., Kelland L. R., Neidle S. A., J. Med. Chem., 44, 138-144 (2001).
12. Soderlind K. J., Gorodetsky B., Singh A. K., Bachur N. R., Miller G. G., Lown J. W., Anti-Cancer Des., 14, 19-36 (1999).
13. Gravatt G. L., Baguley B. C., Wilson W. R., Denny W. A., J. Med. Chem., 37, 4338-4345 (1994).
14. Bielawski K., Bielawska A., Wołczyński S., Biol. Pharm. Bull., 25, 916-919 (2002).
15. Shichita M., Shimazawa R., Nakajima O., Mizoguchi H., Hashimoto Y., Iwasaki S., Biol. Pharm. Bull., 18, 637-639 (1995).
16. Fukutomi R., Kagechika H., Hashimoto Y., Shudo K., Chem. Pharm. Bull., 44, 1983-1985 (1996).
17. Bielawski K., Wołczyński S., Bielawska A., Biol. Pharm. Bull., 24, 704-706 (2001).
18. Tang W., Eisenbrand G., Arch. Pharm. (Weinheim), 314, 910-917 (1981).
19. Ehresmann K., Zelezny O., Eisenbrand G., Arch. Pharm. (Weinheim), 317, 481-487 (1984).
20. Carmichael J., Degraff W., Gazdar A., Minna J., Mitchell J., Cancer Res., 47, 936-942 (1987).
21. Scatchard C., Ann. N.Y. Acad. Sci., 51, 660-672 (1949).
22. Chen A. Y., Liu L. F., Annu. Rev. Pharmacol. Toxicol., 34, 191-218 (1994).
23. Fortune J. M., Osheroff N., Prog. Nucleic Res. Mol. Biol., 64, 221-253 (2000).
24. Champoux J. J., Annu. Rev. Biochem., 70, 369-413 (2001).
25. Ali-Osman F., Berger M. S., Rajagopal S., Spence A., Livingston R. B., Cancer Res., 53, 5663-5668 (1993).